Neuroendocrine Tumors
Conditions
Keywords
positive rate, SUVmax, relationship
Brief summary
68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax of dual imaging associated with pathological findings and prognosis. The study was designed to confirm thet clinical values of dual imagings for neuroendocrine tumors.
Interventions
RADIATION68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET
At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
RADIATION68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC
At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
Sponsors
Peking University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. sign written informed consent form 2. age ≥ 18 years 3. pathologically confirmed neuroendocrine, Ki67\>=10%; 4. ECOG 0-1; 5. No prior antitumor treatment with chemotherapy targeting regimens for neuroendocrine carcimomas, no more than 2 systematic treatment for neuroendocrine tumors; 6. Unresectable disease; 7. At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan \>=20mm, spiral CT scan \>=10mm, no prior radiation to measurable lesions); 8. Predicted survival \>=3 months; 9. Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women; 10. Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
Exclusion criteria
1. In the process of antitumor therapy with effective response; 2. Refuse to accept PET/CT; 3. Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study; 4. Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons；
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The correlation between the positive rate and SUVs of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT and treatment response | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| The correlation between positive rate and SUV of PET/CT and prognosis | 3 year |
| Compare SUVmax, tumor/liver ratio as a prognostic marker | 3 year |
Countries
China
Contacts
Primary ContactLin Shen, Professor
Outcome results
None listed